Table 4. Pharmakinetic Parameters Are Influenced by Tag Placement and Conjugation Chemistry.
| analyte | total ADC half-life (days) | total antibody half-life (days) | total ADC AUCa | total antibody AUCa |
|---|---|---|---|---|
| α-HER2 CTADC | 7.8 ± 0.5 | 16.6 ± 2 | 366 880 | 695 913 |
| α-HER2 LC ADC | 5.2 ± 0.2 | 14.13 ± 1.5 | 289 607 | 678 971 |
| α-HER2 CH1 ADC | 5.7± 0.3 | 15.0 ±1.9 | 275 677 | 617 428 |
| α-HER2-DM1 ADC | 6 ± 0.3 | 10.7 ± 0.7 | 240 082 | 482 220 |
| Trastuzumab | n.a.b | 13.65 ± 1 | n.a.b | 809 674 |
a
Area under the curve (day × ng/mL) for the beta phase, measured from 2 to 28 d.
b
Not applicable.